Compare BXMT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | ADMA |
|---|---|---|
| Founded | 1966 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 1998 | 2012 |
| Metric | BXMT | ADMA |
|---|---|---|
| Price | $12.53 | $9.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $21.38 | ★ $25.67 |
| AVG Volume (30 Days) | 2.0M | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | ★ 154.70 | N/A |
| EPS | N/A | ★ 0.35 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | N/A | $22.11 |
| P/E Ratio | ★ N/A | $27.20 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $12.31 | $7.21 |
| 52 Week High | $20.67 | $20.46 |
| Indicator | BXMT | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 26.46 | 50.95 |
| Support Level | N/A | $9.23 |
| Resistance Level | $14.27 | $9.49 |
| Average True Range (ATR) | 0.34 | 0.34 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 15.57 | 66.54 |
Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.